Incyte Corporation has outperformed the broader healthcare sector, with its stock rising 6.5% over the past three months compared to a 1.5% gain for the State Street Healthcare Select Sector SPDR ETF. Over the past 52 weeks, INCY surged 43.9%, far exceeding the ETF's 12.1% increase. The company's first-quarter 2026 revenue of $1.3 billion and adjusted earnings per share of $1.81 both topped Wall Street estimates. Analysts hold a consensus Moderate Buy rating on the stock with a mean price target of $111.26, implying a 13.3% upside from current levels.
Incyte CorporationIncyte's Q1 revenue and EPS beat estimates, and analysts have a Moderate Buy rating with upside.
Insmed Inc
Meta Platforms Inc.